


Year <sup>1</sup>	Actiq (Sales and Marketing)	Fentora (Sales and Marketing)	Total
2006	--	\$24,910,000	\$24,910,000
2007	--	\$32,959,000	\$32,959,000
2008	--	\$20,964,000	\$20,964,000
2009	--	\$18,849,000	\$18,849,000
2010	--	\$22,026,000	\$22,026,000
2011	--	\$22,519,000	\$22,519,000
2012	--	\$5,573,000 <sup>2</sup>	\$5,573,000 <sup>3</sup>
2013	\$73,937	\$35,000,743	\$35,074,680
2014	\$781,316	\$29,417,904	\$30,199,220
2015	\$262,484	\$19,392,410	\$19,654,894
2016	\$176,750	\$11,016,291	\$11,193,041

Sources:

TEVA-OK-02321353, Actiq and Fentora 2006- Q1 2012

TEVA\_OK\_01218820, Fentora Actiq Budget Actuals



<sup>1</sup> The figures in this table are based on the information located by the Teva Defendants to date. The Teva Defendants reserve the right to supplement these figures if/when additional information becomes available.

<sup>2</sup> Only reflects the first quarter of 2012.

<sup>3</sup> Only reflects the first quarter of 2012.

**CONFIDENTIAL**

**PLAINTIFFS TRIAL  
EXHIBIT  
P-29945\_00001**